Analysts’ View: Alnylam Pharmaceuticals (ALNY), NeoPhotonics (NPTN), Corporate Office Properties (OFC)

Brokerage Firm Stifel upgraded Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) shares from Hold to Buy rating while increasing their price target from $95 to $125.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference.


NeoPhotonics Corporation (NYSE:NPTN) shares were upgraded by analysts at B. Riley FBR from Neutral to Buy rating while increasing their price target from $6.50 to $10.

NeoPhotonics Corporation develops, manufactures, and sells optoelectronic products that transmit, receive, and switch high speed digital optical signals for communications networks.


Investment Analysts at BofA/Merrill upgraded Corporate Office Properties Trust (NYSE:OFC) shares from Neutral to Buy rating.

Corporate Office Properties Trust is a REIT that owns, manages, leases, develops and selectively acquires office and data center properties in locations that support the United States Government and its contractors, most of whom are engaged in national security, defense and information technology (IT) related activities servicing what it believes are growing, durable, priority missions (Defense/IT Locations)


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at